MaxCyte Reports Q4 and FY25 Financial Results, Initiates 2026 Guidance

MaxCyte reported Q4 2025 total revenue of $7.3 million, at the top of its previous preliminary announcement, and full-year 2025 revenue of $33 million, also at the top of its preliminary range. The company expects to end 2026 with at least $136 million in total cash, cash equivalents, and investments. For 2026, MaxCyte expects revenue of $30-32 million, with core revenue of $25-27 million and SPL Program-related revenue of $5 million.